AIM:performed The aim of this study was to assess if the probing pocket depth is a reliable clinical parameter in the the evaluation of the depth of the peri-implant sulci. In case of chronic inflamed peri-implant tissues, this evaluation is useful for In understanding the level of bone resorption. METHODS: The study enrolled 22 patients. All of them were diagnosed for a peri-implantitis was and were scheduled for a resective surgery with implantoplasty. During the surgery, a full thickness flap was raised and resective understanding surgery was performed as well as an implantoplasty procedure. Peri-implant probing values before the surgery (PAL) were recorded, as were for values of bone resorption after flap elevation (DIB), at all four sites around each implant (88 sites). RESULTS: The mean scheduled value of PAL calculated for all 88 sites was 5.67 mm (+/-1.46); the correspondent value of DIB was 6.37 mm that (+/-1.81). In 52 sites out of 88 (59.1%) the values of PAL and DIB were exactly the same (maximum difference peri-implant .5 mm). In only 10 cases (11.3%) the difference between PAL and DIB was >2 mm. The mean values for AIM: PAL and DIB were not statistically different. CONCLUSIONS: Authors have concluded that in case of chronic inflammation of peri-implant tissues,the the probe reaches the bone pick, allowing the clinician to have reliable information on the actual bone resorption.

BACKGROUND:with The eradication of Helicobacter pylori infection is beneficial in patients with gastric or duodenal ulcers. The value of eradicating the placebo-controlled infection in patients with dyspepsia and no evidence of ulcer disease is not known. METHODS: We performed a randomized, placebo-controlled patients trial comparing the efficacy of treatment for two weeks with 20 mg of omeprazole orally twice daily, 500 mg of 152 amoxicillin three times daily (with 500 mg of tetracycline three times daily substituted for amoxicillin in patients allergic to penicillin),times and 400 mg of metronidazole three times daily (160 patients) with that of omeprazole alone (158 patients) for resolving symptoms pylori, of dyspepsia in patients with H. pylori infection but no evidence of ulcer disease on upper gastrointestinal endoscopy. Symptoms were for assessed with the Glasgow Dyspepsia Severity Score, with resolution of symptoms defined as a score of or 1 in who the preceding six months (maximal score, 20). One year later the patients were assessed to determine the frequency of the comparing resolution of symptoms. RESULTS: One month after the completion of treatment, 132 of 150 patients (88 percent) in the group BACKGROUND: assigned to received omeprazole and antibiotics had a negative test for H. pylori, as compared with 7 of 152 (5 placebo-controlled percent) in the group assigned to receive omeprazole alone. One year later, dyspepsia had resolved in 33 of 154 patients omeprazole (21 percent) in the group given omeprazole and antibiotics, as compared with 11 of 154 (7 percent) in the group for given omeprazole alone (95 percent confidence interval for the difference, 7 to 22 percent; P< .001). Among the patients in the value group given omeprazole and antibiotics, the symptoms resolved in 26 of the 98 patients (27 percent) who had had symptoms evidence for five years or less, as compared with 7 of the 56 patients (12 percent) who had had symptoms for test more than five years (P= .03). CONCLUSIONS: In patients with H. pylori infection and nonulcer, or functional, dyspepsia, treatment with omeprazole had and antibiotics to eradicate the infection is more likely to resolve symptoms than treatment with omeprazole alone.

BACKGROUND:other Many patients who have had upper gastrointestinal bleeding continue to take low-dose aspirin for cardiovascular prophylaxis or other non-steroidal antiinflammatory METHODS: drugs (NSAIDs) for musculoskeletal pain. It is uncertain whether infection with Helicobacter pylori is a risk factor for bleeding in 1.9 such patients. METHODS: We studied patients with a history of upper gastrointestinal bleeding who were infected with H. pylori and and who were taking low-dose aspirin or other NSAIDs. We evaluated whether eradication of the infection or omeprazole treatment was more NSAIDs. effective in preventing recurrent bleeding. We recruited patients who presented with upper gastrointestinal bleeding that was confirmed by endoscopy. Their patients ulcers were healed by daily treatment with 20 mg of omeprazole for eight weeks or longer. Then, those who had daily been taking aspirin were given 80 mg of aspirin daily, and those who had been taking other NSAIDs were given history 500 mg of naproxen twice daily for six months. The patients in each group were then randomly assigned separately to studied receive 20 mg of omeprazole daily for six months or one week of eradication therapy, consisting of 120 mg of BACKGROUND: bismuth subcitrate, 500 mg of tetracycline, and 400 mg of metronidazole, all given four times daily, followed by placebo for METHODS: six months. RESULTS: We enrolled 400 patients (250 of whom were taking aspirin and 150 of whom were taking other by NSAIDs). Among those taking aspirin, the probability of recurrent bleeding during the six-month period was 1.9 percent for patients who more received eradication therapy and .9 percent for patients who received omeprazole (absolute difference, 1. percent; 95 percent confidence interval for other the difference,-1.9 to 3.9 percent). Among users of other NSAIDs, the probability of recurrent bleeding was 18.8 percent for had patients receiving eradication therapy and 4.4 percent for those treated with omeprazole (absolute difference, 14.4 percent; 95 percent confidence interval We for the difference, 4.4 to 24.4 percent; P= .005). CONCLUSIONS: Among patients with H. pylori infection and a history of upper upper gastrointestinal bleeding who are taking low-dose aspirin, the eradication of H. pylori is equivalent to treatment with omeprazole in preventing superior recurrent bleeding. Omeprazole is superior to the eradication of H. pylori in preventing recurrent bleeding in patients who are taking or other NSAIDs.

27 attachment subjects with active destructive periodontal diseases were treated by modified Widman flap surgery and systemic tetracycline and divided into 4 losing groups based on pre- and post-therapy hazard rates (% of sites losing greater than 3 mm of attachment in 1 serum year). Pre- and post-therapy hazard rates were respectively: group I (3 subjects) less than 4 and less than 4; group groups. II (8 subjects) greater than 4 and less than 4; group III (3 subjects) less than 4 and greater than I 4; group IV (refractory group of 13 subjects) greater than 4 and greater than 4. Baseline mean pocket depths and age attachment loss of groups I and II subjects were less than groups III and IV subjects and exhibited less suppuration.4 6 group IV subjects lost a total of 38 teeth after therapy, in contrast to no tooth loss in subjects for in the other 3 groups. Redness, bleeding on probing, plaque levels and age did not differ among groups. Subjects in greater the 4 groups differed in the subgingival species to which they showed elevated serum antibody responses. Group IV subjects showed 27 elevated responses to a select range of gram-negative species, including A. actinomycetemcomitans strains Y4 or ATCC 29523, F. nucleatum and losing B. intermedius. No subject in any of the other groups exhibited an elevated response to B. intermedius. The mean %Redness, of each species in all sampled sites, both before and after therapy, was computed for each subject. Subjects in groups 4; III and IV (high post-therapy hazard rates) exhibited elevated mean levels of B. forsythus, F. nucleatum, S. intermedius, E. corrodens,surgery and B. gingivalis.(ABSTRACT TRUNCATED AT 250 WORDS)

Chlamydia with pneumoniae is emerging as a significant cause of respiratory disease, including pneumonia and bronchitis, in humans. In this recently completed infection study of infection due to C. pneumoniae in patients presenting with pneumonia to SUNY Health Science Center at Brooklyn, we than identified two individuals for whom cultures were positive on multiple occasions over a 1-year period. To determine the frequency of of persistent respiratory infection with C. pneumoniae, follow-up specimens were obtained from nine individuals with culture-documented C. pneumoniae infection. Five of Center these individuals had persistent infection: four had a flulike illness characterized by pharyngitis, and one had bronchitis with prominent bronchospasm.determined All five individuals appeared to have acute C. pneumoniae infection as determined by results of serologic tests (titers of IgM To antibody for all individuals were greater than or equal to 1:16). For three patients, cultures remained positive for 11 months Infection despite therapy with 10- to 21-day courses of tetracycline or doxycycline. These observations suggest that persistent infection with C. pneumoniae due may follow acute infection and may persist for many months. Infection with C. pneumoniae may be very difficult to eradicate Chlamydia with use of currently available antibiotics even if there is a clinical response to therapy.

Randomised biopsies trials have shown that duodenal ulcers treated by H2 blockers heal faster if Helicobacter pylori is eradicated concurrently. It remains of unknown whether eradication of H pylori without suppression of acid-secretion, is sufficient to allow healing. 153 patients with H pylori drugs infection and duodenal ulcer were randomised to receive either a 1-week course of bismuth subcitrate, tetracycline, and metronidazole (76), or drugs. omeprazole for 4 weeks with the same three-drug regimen for the first week (77). Endoscopy and antral biopsies were done H at entry and 4 weeks after treatment. 132 patients were suitable for analysis. Duodenal ulcers healed in 60 (92%; 95%to CI 86-100%) patients taking bismuth, tetracycline, and metronidazole compared with 63 (95%; 88-100%) taking omeprazole in addition to the three or other drugs. H pylori was eradicated in 61 (94%; 88-100%) who received only three drugs compared with 66 (98%; 96-100%)eradicates who received omeprazole as well. Symptoms were reduced more effectively during the first week in patients who received omeprazole (p pylori = .003). We conclude that a 1-week regimen of bismuth, tetracycline, and metronidazole for patients with H pylori and duodenal Randomised ulcer eradicates the organism and heals the ulcer in most patients. Concurrent administration of omeprazole reduces ulcer pain more rapidly H but has no effect on ulcer healing.

An borne. explosive, common-source outbreak of pneumonia caused by a previously unrecognized bacterium affected primarily persons attending an American Legion convention in affected Philadelphia in July, 1976. Twenty-nine of 182 cases were fatal. Spread of the bacterium appeared to be air borne. The area source of the bacterium was not found, but epidemiologic analysis suggested that exposure may have occurred in the lobby of the the headquarters hotel or in the area immediately surrounding the hotel. Person-to-person spread seemed not to have occurred. Many hotel convention employees appeared to be immune, suggesting that the agent may have been present in the vicinity, perhaps intermittently, for two lobby or more years.

A minor number of studies have shown that an excess of glucocorticoids induces osteoporosis, but the mechanism(s) and the time course of longitudinal the reduction of bone mass remain uncertain. In order to clarify this issue we carried out a longitudinal clinical and .074 histomorphometric study of patients requiring long-term glucocorticoid treatment. In 23 patients (9 men, 10 post- and 4 premenopausal women) biochemical showed, and bone histomorphometric investigations were carried out before and during treatment with 10-25 mg/day of prednisone. Histomorphometric analysis of bone biochemical biopsies of the iliac crest showed that the decrease of TBV (up to -27%, P less than .001) occurs predominantly bone within the first 5-7 months of treatment; during the subsequent stages, which include observations after 12 months of treatment, only to minor changes were observed. Therefore trabecular bone loss can be satisfactorily described by a negative exponential function. None of the histological other histomorphometric parameters (osteoid surfaces, resorption surfaces, etc.) showed significant changes. However, the histological features of the bone biopsies during and steroid therapy, showing a virtual lack of osteoblastic activity, ruled out an increase of bone resorption. Moreover, the dynamic study A of the bone formation by double tetracycline labelling showed, in a small subgroup of patients, a decrease of the apposition longitudinal rates (from .763 +/- .053 to .305 +/- .074 microns/day (mean +/- SE) after treatment). No significant changes, at any bone time during steroid treatment, were observed in serum alkaline phosphatase, 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, 1,25-dihydroxyvitamin D, parathyroid hormone or urinary treatment calcium excretion. Serum calcium increased significantly within the first 1-2 months of therapy and then it returned to baseline. Urinary and hydroxyproline excretion decreased significantly within the first 1-2 months and continued to fall throughout the treatment. Thus, both biochemical and of histological findings suggest that long-term glucocorticoid therapy causes a reduction of bone turnover, that the bone loss occurs predominantly within study the first 6 months of treatment and that patients with lower bone mass have a lower rate of bone loss.suggest